A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

NCT01849874

Last updated date
Study Location
Phoenix, Arizona, , United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of LGS carcinoma of the ovary, fallopian tube or primary peritoneum (invasive micropapillary serous carcinoma or invasive grade 1 serous carcinoma), confirmed histologically and verified by central pathology review.

- Recurrent or persistent measurable disease that has progressed (defined as radiological and/or clinical progression; an increase in cancer antigen [CA]-125 alone is not sufficient) on or after last therapy (i.e., chemotherapy, hormonal therapy, surgery) and is not amenable to potentially curative intent surgery, as determined by the patient's treating physician.

- Must have received at least 1 prior platinum-based chemotherapy regimen but have received no more than 3 lines of prior chemotherapy regimens, with no limit to the number of lines of prior hormonal therapy. Front-line therapy may include neoadjuvant and adjuvant therapy and will be counted as 1 prior systemic regimen. Biological therapy (e.g. bevacizumab) administered as a single agent is considered a prior systemic regimen and not a prior chemotherapy regimen. Maintenance therapy is not considered its own regimen but should be included with the regimen that it follows.

- Available archival tumor sample (excisional or core biopsy) for confirmation of LGS carcinoma diagnosis. If adequate archival tumor sample is not available, willingness to consent to tissue biopsy.

- Suitable for treatment with at least one of the physician's choice chemotherapy options (liposomal doxorubicin, paclitaxel or topotecan) as determined by the Investigator.

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

- Additional criteria exist.

Key

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- History or current evidence of retinal vein occlusion (RVO) or current risk factors
for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity
or hypercoagulability syndromes).


- Prior therapy with a MEK or BRAF inhibitor.


- History of Gilbert's syndrome.


- Impaired cardiovascular function or clinically significant cardiovascular diseases.


- Uncontrolled or symptomatic brain metastases that are not stable or require steroids,
are potentially life-threatening or have required radiation within 28 days prior to
first dose of study treatment.


- Concomitant malignancies or previous malignancies with less than a 5-year disease-free
interval at the time of first dose of study treatment; patients with adequately
resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix
or ductal carcinoma in situ may be enrolled irrespective of the time of diagnosis.


- Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B
and/or active hepatitis C.


- Prior randomization into this clinical study.


- Additional criteria exist.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal CancerA Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
NCT01849874
  1. Phoenix, Arizona
  2. Scottsdale, Arizona
  3. Irvine, California
  4. Los Angeles, California
  5. Aurora, Colorado
  6. New Haven, Connecticut
  7. Orlando, Florida
  8. Tampa, Florida
  9. West Palm Beach, Florida
  10. Augusta, Georgia
  11. Chicago, Illinois
  12. Indianapolis, Indiana
  13. Iowa City, Iowa
  14. Baltimore, Maryland
  15. Boston, Massachusetts
  16. Detroit, Michigan
  17. Grand Rapids, Michigan
  18. Saint Louis, Missouri
  19. Billings, Montana
  20. Albuquerque, New Mexico
  21. Bronx, New York
  22. New York, New York
  23. Cincinnati, Ohio
  24. Cleveland, Ohio
  25. Columbus, Ohio
  26. Oklahoma City, Oklahoma
  27. Philadelphia, Pennsylvania
  28. Pittsburgh, Pennsylvania
  29. Dallas, Texas
  30. Houston, Texas
  31. Charlottesville, Virginia
  32. Adelaide,
  33. Footscray,
  34. Nedlands,
  35. South Brisbane,
  36. Sydney,
  37. Toorak Gardens,
  38. Westmead,
  39. Innsbruck,
  40. Vienna,
  41. Bruxelles,
  42. Edegem,
  43. Gent,
  44. Leuven,
  45. Libramont,
  46. Liege,
  47. Liege,
  48. Namur,
  49. Wilrijk,
  50. Calgary, Alberta
  51. Vancouver, British Columbia
  52. Winnipeg, Manitoba
  53. Hamilton, Ontario
  54. Toronto, Ontario
  55. Montreal, Quebec
  56. Sherbrooke, Quebec
  57. Brno,
  58. Hradec Kralove,
  59. Olomouc,
  60. Ostrava-Poruba,
  61. Prague,
  62. Prague,
  63. Aalborg,
  64. Copenhagen,
  65. Harlev,
  66. Tampere,
  67. Angers,
  68. Besancon,
  69. Lille,
  70. Lyon,
  71. Marseille,
  72. Montpellier,
  73. Nantes,
  74. Paris,
  75. Paris,
  76. Saint-Brieuc,
  77. Saint-Herblain,
  78. Strasbourg,
  79. Villejuif,
  80. Aachen,
  81. Berlin,
  82. Bonn,
  83. Dresden,
  84. Erlangen,
  85. Essen,
  86. Essen,
  87. Frankfurt,
  88. Freiburg,
  89. Gottingen,
  90. Greifswald,
  91. Hannover,
  92. Heidelberg,
  93. Jena,
  94. Kassel,
  95. Kiel,
  96. Lubeck,
  97. Marburg,
  98. Munich,
  99. Tubingen,
  100. Ulm,
  101. Budapest,
  102. Budapest,
  103. Budapest,
  104. Gyor,
  105. Miskolc,
  106. Nyiregyhaza,
  107. Dublin,
  108. Aviano,
  109. Bari,
  110. Bari,
  111. Bologna,
  112. Brescia,
  113. Catania,
  114. Faenza,
  115. Faenza,
  116. Milano,
  117. Milan,
  118. Milan,
  119. Naples,
  120. Naples,
  121. Pisa,
  122. Roma,
  123. Roma,
  124. Esch-sur-Alzette,
  125. Amsterdam,
  126. Groningen,
  127. Maastricht,
  128. Bergen,
  129. Oslo,
  130. Poznan,
  131. Szczecin,
  132. Warszawa,
  133. Avila,
  134. Barcelona,
  135. Barcelona,
  136. Barcelona,
  137. Cordoba,
  138. Madrid,
  139. Madrid,
  140. Malaga,
  141. Oviedo,
  142. Palma de Mallorca,
  143. San Sebastian,
  144. Santiago de Compostela,
  145. Sevilla,
  146. Toledo,
  147. Valencia,
  148. Stockholm,
  149. Uppsala,
  150. Birmingham,
  151. London,
  152. London,
  153. Manchester,
  154. Nottingham,
  155. Sutton,
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
Official Title  ICMJE Not Provided
Brief Summary The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum will receive either investigational study drug MEK162 or a chemotherapy chosen by the physician (liposomal doxorubicin, paclitaxel or topotecan). Patients will be followed to compare the effectiveness of the study drug to that of the selected chemotherapies. Patients may be eligible to crossover from physician's choice chemotherapy to MEK162 if they meet certain inclusion criteria including centrally confirmed disease progression. Approximately 360 patients from North America, Europe and Australia will be enrolled in this study.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Low-grade Serous Ovarian Cancer
  • Low-grade Serous Fallopian Tube Cancer
  • Low-grade Serous Peritoneal Cancer
Intervention  ICMJE
  • Drug: MEK162, MEK inhibitor; oral
    multiple dose, single schedule
  • Drug: Physician's choice chemotherapy

    Patients will receive one of the following chemotherapies as determined by the physician:

    • Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)
    • Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)
    • Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)
Study Arms  ICMJE
  • Experimental: MEK162
    Intervention: Drug: MEK162, MEK inhibitor; oral
  • Active Comparator: Physician's choice chemotherapy
    Intervention: Drug: Physician's choice chemotherapy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: April 14, 2015)
360
Original Estimated Enrollment  ICMJE
 (submitted: May 7, 2013)
300
Estimated Study Completion Date  ICMJE September 30, 2021
Actual Primary Completion Date April 1, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria:

  • Diagnosis of LGS carcinoma of the ovary, fallopian tube or primary peritoneum (invasive micropapillary serous carcinoma or invasive grade 1 serous carcinoma), confirmed histologically and verified by central pathology review.
  • Recurrent or persistent measurable disease that has progressed (defined as radiological and/or clinical progression; an increase in cancer antigen [CA]-125 alone is not sufficient) on or after last therapy (i.e., chemotherapy, hormonal therapy, surgery) and is not amenable to potentially curative intent surgery, as determined by the patient's treating physician.
  • Must have received at least 1 prior platinum-based chemotherapy regimen but have received no more than 3 lines of prior chemotherapy regimens, with no limit to the number of lines of prior hormonal therapy. Front-line therapy may include neoadjuvant and adjuvant therapy and will be counted as 1 prior systemic regimen. Biological therapy (e.g. bevacizumab) administered as a single agent is considered a prior systemic regimen and not a prior chemotherapy regimen. Maintenance therapy is not considered its own regimen but should be included with the regimen that it follows.
  • Available archival tumor sample (excisional or core biopsy) for confirmation of LGS carcinoma diagnosis. If adequate archival tumor sample is not available, willingness to consent to tissue biopsy.
  • Suitable for treatment with at least one of the physician's choice chemotherapy options (liposomal doxorubicin, paclitaxel or topotecan) as determined by the Investigator.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
  • Additional criteria exist.

Key Exclusion Criteria:

  • History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes).
  • Prior therapy with a MEK or BRAF inhibitor.
  • History of Gilbert's syndrome.
  • Impaired cardiovascular function or clinically significant cardiovascular diseases.
  • Uncontrolled or symptomatic brain metastases that are not stable or require steroids, are potentially life-threatening or have required radiation within 28 days prior to first dose of study treatment.
  • Concomitant malignancies or previous malignancies with less than a 5-year disease-free interval at the time of first dose of study treatment; patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or ductal carcinoma in situ may be enrolled irrespective of the time of diagnosis.
  • Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or active hepatitis C.
  • Prior randomization into this clinical study.
  • Additional criteria exist.
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Austria,   Belgium,   Canada,   Czechia,   Denmark,   Finland,   France,   Germany,   Hungary,   Ireland,   Italy,   Luxembourg,   Netherlands,   Norway,   Poland,   Spain,   Sweden,   United Kingdom,   United States
Removed Location Countries Czech Republic
 
Administrative Information
NCT Number  ICMJE NCT01849874
Other Study ID Numbers  ICMJE ARRAY-162-311
2013-000277-72 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP